Maze Therapeutics (MAZE) Insider: 18,000 Stock Options at $23.67

Maze Therapeutics director Jonathan E. Lim received a grant of stock options.

Rhea-AI Filing Summary

Maze Therapeutics director Jonathan E. Lim received a grant of stock options. The Form 4 reports an award of 18,000 stock options with an exercise price of $23.67, dated 09/22/2025. The options have an exercise price of $23.67 and underlying 18,000 shares of common stock, with an expiration date of 09/21/2035.

The filing states the option vests monthly as to 1/9 of the total award, beginning with a first tranche vesting on 10/01/2025, subject to continued service. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 09/24/2025.

Positive

• 18,000 stock options granted to director Jonathan E. Lim, clearly documented in the Form 4
• Full grant economics disclosed: exercise price $23.67 and expiration date 09/21/2035

Negative

• None.

Insights

Securities Analyst

TL;DR: Director Jonathan Lim was granted 18,000 options at $23.67 exercisable through 2035 with monthly vesting starting October 1, 2025.

The reported transaction is a typical director option grant: 18,000 options priced at $23.67, expiring 09/21/2035. Vesting is specified as 1/9 monthly tranches beginning 10/01/2025, contingent on continued service. This disclosure is routine under Section 16 filing rules and provides clear timelines and quantities for potential future share issuance and dilution.

Corporate Governance Expert

TL;DR: The Form 4 documents standard equity compensation for a director with explicit vesting schedule and long-term exercise window.

The grant is documented with precise terms: grant date 09/22/2025, exercise price $23.67, 18,000 options, exercisable through 09/21/2035, and vesting in nine monthly tranches starting 10/01/2025. The filing was executed by an attorney-in-fact on 09/24/2025. The disclosure meets reporting requirements and clarifies timing of potential ownership changes.

Insider Trade Summary

Grant/Award: 18,000 shares

Grant/Award 1 txn

Insider Lim Jonathan E

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	18,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 18,000 contracts (Direct)

Footnotes (1)

1. F1. The option shall vest as to 1/9 of the total award monthly with the first tranche vesting on October 1, 2025, subject to the reporting person's continued service to the Issuer on the applicable vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Jonathan E. Lim report on Form 4 for MAZE?

The Form 4 reports a grant of 18,000 stock options dated 09/22/2025 with an exercise price of $23.67 and expiration 09/21/2035.

When do the options granted to the MAZE director begin vesting?

Vesting begins 10/01/2025 and the award vests as to 1/9 of the total award monthly, subject to continued service.

How many shares underlie the derivative security in the Form 4 for MAZE?

The derivative security underlies 18,000 shares of Maze Therapeutics common stock.

What is the exercise price and expiration for the granted options in the MAZE filing?

The exercise price is $23.67 and the options expire on 09/21/2035.

Who signed the Form 4 for Jonathan E. Lim and when?

The Form 4 was signed by Courtney Phillips, as attorney-in-fact, on 09/24/2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/24/2025 - 04:17 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Lim Jonathan E

(Last) (First) (Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$23.67	09/22/2025		A		18,000		(1)	09/21/2035	Common Stock	18,000	$0	18,000	D

Explanation of Responses:

1. The option shall vest as to 1/9 of the total award monthly with the first tranche vesting on October 1, 2025, subject to the reporting person's continued service to the Issuer on the applicable vesting date.

	/s/ Courtney Phillips, as attorney-in-fact	09/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.